Holen Sie sich die Stockscreener-App
6.26
1.25%
-0.14
Schlusskurs vom Vortag:
$6.40
Offen:
$6.4
24-Stunden-Volumen:
41,404
Relative Volume:
0.85
Marktkapitalisierung:
$97.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.36M
KGV:
-4.7192
EPS:
-1.3265
Netto-Cashflow:
$-11.39M
1W Leistung:
+8.97%
1M Leistung:
+23.44%
6M Leistung:
-37.61%
1J Leistung:
+42.99%
1-Tages-Spanne:
$6.12
$6.59
1-Wochen-Bereich:
$5.65
$6.59
52-Wochen-Spanne:
$3.21
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Firmenname
Coya Therapeutics Inc
Sektor
Branche
Telefon
650.739.3939
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright - MarketBeat
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update - MarketBeat
Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation - Yahoo Finance
Coya Therapeutics to Present at Upcoming Healthcare Conferences - StockTitan
Coya Therapeutics promotes Arun Swaminathan to CEO post - The Pharma Letter
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics appoints new CEO, founder shifts role - Investing.com
Coya Therapeutics Names Arun Swaminathan Chief Executive - MarketWatch
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - Manchestertimes
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) to Post FY2024 Earnings of ($1.17) Per Share, Chardan Capital Forecasts - MarketBeat
Vanguard Group Inc. Has $8.41 Million Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc. - Defense World
Coya Therapeutics, Inc. (NASDAQ:COYA) Forecasted to Earn FY2025 Earnings of ($1.26) Per Share - MarketBeat
Chardan Capital Weighs in on Coya Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:COYA) - Defense World
Frontotemporal Dementia Market to Show Remarkable Growth - openPR
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - Manchestertimes
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - wallstreet:online
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - Defense World
Coya Therapeutics Blunders on Test Results - MSN
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com India
Coya reports Alzheimer's trial to present at CTAD24 - Investing.com
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com Canada
Coya Therapeutics Blunders on Test Results - Baystreet.ca
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid - Chronicle-Tribune
Coya Therapeutics files for IP on novel therapy combination - Investing.com
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - StockTitan
Long Term Trading Analysis for (COYA) - Stock Traders Daily
(COYA) Investment Report - Stock Traders Daily
Coya Shares Rise After Next Step to New Study of ALS Treatment - MarketWatch
Coya Therapeutics faces FDA hold on ALS drug study - Investing.com
individual investors who own 58% along with institutions invested in Coya Therapeutics, Inc. (NASDAQ:COYA) saw increase in their holdings value last week - Simply Wall St
Coya Therapeutics faces FDA hold on ALS drug study By Investing.com - Investing.com Canada
Coya Therapeutics (NASDAQ:COYA) Shares Down 2.7% - MarketBeat
Howard Berman, CEO and co-founder of Coya Therapeutics - InnovationMap
3 Houston health tech innovators to know this week - InnovationMap
Trend Tracker for (COYA) - Stock Traders Daily
Coya Therapeutics - The Pharma Letter
Coya extends research collaboration into exosomes from T-cells - Parkinson's News Today
Form 424B3 Coya Therapeutics, Inc. - StreetInsider.com
COYACoya Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with ... - StockTitan
Investor's Toolkit: Key Ratios for Assessing Coya Therapeutics Inc (COYA)'s Performance – DWinneX - The Dwinnex
COYA 302 slows ALS progression, lowers biomarkers: Trial - ALS News Today
COYA 302 slows disease progression, lowers biomarkers: Trial - ALS News Today
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 20.0% in May - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
Coya Therapeutics (NASDAQ:COYA) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):